Biotech Values

[DewDiligence]

>> …do you believe the fact that the trials were done outside the U.S. causes them to be taken less seriously? <<

Unfortunately, yes. Wall Street types are heavily biased against trials in third-world countries. Even Dr. Ron Garren, the editor of the InvestBio newsletter who recently recommended GENR at $6.22, admitted to being skeptical of Squalamine because the phase ½ trial was conducted in Mexico.

>> Why would GENR have chosen to go this route in the first place? <<

Two reasons: 1) Cheaper; and 2) Easier to recruit patients because Visudyne treatment was not as widely available in Mexico.